Rowook Park

• 35Pharma in its approximately $1 billion sale to GSK*
• Accriva Diagnostics, a medical device portfolio company controlled by Warburg Pincus, in its acquisition by Werfen for $380 million*
• Amplyx in its sale to Pfizer for an undisclosed amount*
• Arena Pharmaceuticals in its global license and sale of related assets to United Therapeutics for Arena’s drug candidate ralinepag for an upfront payment of $800 million, milestone payments totaling up to $400 million and additional payments in royalties; and in a sale and assignment of certain drug product finishing facility assets and know-how to Siegfried for an undisclosed amount*
• Bayer AG in its $66 billion acquisition of Monsanto*
• Biotheranostics in its $230 million acquisition by Hologic*
• Bridge to Life in its sale of certain assets to TransMedics*
• Calimmune in its acquisition by CSL Behring for an upfront payment of $91 million, plus potential future milestone payments of up to $325 million*
• Cidara Therapeutics in its $9.2 billion sale to Merck*
• CinCor Pharma, a clinical-stage biopharmaceutical company, on its sale to AstraZeneca for up to $1.8 billion*
• Counsyl in its acquisition by Myriad Genetics for $375 million in cash and common stock*
• Dyax in its $6.5 billion acquisition by Shire*
• EsoBiotec in its up to $1 billion sale to AstraZeneca*
• Formation Biologics (dba Forbius) in its acquisition by Bristol Myers Squibb*
• Forty Seven in its $4.9 billion acquisition by Gilead*
• Golden Hour Data Systems in its sale to ZOLL Medical, an Asahi Kasei Group company*
• Gracell Biotechnologies in its $1.2 billion sale to AstraZeneca*
• Horizon Therapeutics in its $28.3 billion sale to Amgen; in its $3.1 billion acquisition of Viela Bio; and in its acquisition of Tepezza for an upfront cash consideration of $145 million, plus potential future milestone and earnout payments contingent on the satisfaction of certain regulatory milestones and sales thresholds*
• Idenix Pharmaceuticals in its $3.85 billion acquisition by Merck*
• Immunovant in its deSPAC business combination with Health Sciences Acquisitions Corporation, a special purpose acquisition company (SPAC)*
• Impax Laboratories in its $700 million acquisition of Tower Holdings, its operating subsidiaries, and Lineage Therapeutics*
• Lengo Therapeutics in its sale to Blueprint Medicines for up to $465 million*
• Mannkind in its acquisition of scPharmaceuticals*
• Neogene Therapeutics in its up to $320 million sale to AstraZeneca*
• Poseida Therapeutics in its $1.5 billion sale to Roche*
• ProfoundBio in its $1.8 billion sale to Genmab*
• Prothena Biosciences in its sale of Neotope Neuroscience to Novo Nordisk for an upfront payment of $60 million in cash, and up to an additional $1.23 billion in cash upon the achievement of certain development, commercialization, and sales milestones*
• RayzeBio in its $4.1 billion sale to Bristol Myers Squibb*
• SiteOne Therapeutics in its $1 billion sale to Eli Lilly*
• Sucampo in its $1.2 billion acquisition by Mallinckrodt*
• Turning Point Therapeutics in its $4.1 billion sale to Bristol Myers Squibb*
• VelosBio in its $2.75 billion acquisition by Merck*
• ViaCyte in its $320 million sale to Vertex*
• Vividion Therapeutics in its sale to Bayer for up to $2 billion*

• 6degrees.xyz in its sale to Niantic*
• BroadSoft in its $1.9 billion acquisition by a multinational technology company*
• Columbia Pipeline Group in its $13 billion acquisition by TransCanada*
• Cornerstone OnDemand in its $5.2 billion sale to Clearlake Capital Group*
• Ellie Mae in its $3.7 billion acquisition by Thoma Bravo*
• A leading food and beverage company in its $55 billion merger with another major food company*
• Lion Capital and Bumble Bee Foods in the $1.51 billion proposed acquisition of Bumble Bee Foods by Thai Union Frozen Products (later withdrawn)*
• Meredith in its $2.85 billion acquisition of Time; the $2.825 billion sale of its Local Media Group to Gray Television; and its spinoff and sale of National Media Group to IAC’s Dotdash*
• Nikkiso in its acquisition of ACD, Cosmodyne, Cryoquip, and Cryogenic Industries from Cryogenic Industries and its affiliates for a cash consideration of $438 million*
• Paidy in its $2.7 billion sale to PayPal, which was named M&A Deal of the Year at IFLR’s 2022 Asia-Pacific Awards*
• Quanergy in its $970 million deSPAC business combination with CITIC Capital Acquisition, a SPAC*
• SendGrid in its $2 billion acquisition by Twilio for an all-stock consideration*

• Centerview, as financial advisor in connection with the acquisition of Chinook Therapeutics by Novartis for up to $3.5 billion; the $3 billion acquisition of Audentes Therapeutics by Astellas; the $2.3 billion acquisition of Ra Pharmaceuticals by UCB; the $540 million acquisition of BioSpecifics by Endo; and the $1.1 billion acquisition of Forma Therapeutics by Novo Nordisk*
• Morgan Stanley, as financial advisor in connection with the $18.5 billion acquisition of Livongo Health by Teladoc; the $3.3 billion acquisition of Poly by HP; and the $1.7 billion proposed acquisition of iRobot by Amazon (later withdrawn)*
• Perella Weinberg Partners, as financial advisor in connection with the $614 million acquisition of Cascadian Therapeutics by Seattle Genetics*
• Qatalyst Partners, as financial advisor in connection with the $3.4 billion acquisition of Verifone Systems by an investor group led by Francisco Partners and a Canadian institutional investor; the $2.1 billion acquisition of Imperva by Thoma Bravo; the $1.94 billion acquisition of Apptio by Vista Equity Partners; the $2.1 billion acquisition of Fitbit by Google; the $10 billion merger of Inphi and Marvell; the sale of Vonage to Ericsson; and the $1.7 billion acquisition of Sumo Logic by Francisco Partners*

• Ro also advises on corporate and transactional matters for clients including Dunamu, a decacorn and the operator of the largest cryptocurrency exchange in Korea, Hanwha, Qcells and their respective affiliates, Levvels, a joint venture between Dunamu (a crypto decacorn) and Hybe (a record label and talent agency for artists, including BTS), LG Electronics, Nexon, a leading online gaming company, NHN, Riman, and SK Global Chemical.*

*Denotes experience prior to joining Goodwin